Who benefits from Kesimpta®
no subtitles
Discover the benefits to use Kesimpta® and for which patients
Who benefits from Kesimpta®
EN subtitles
Discover the benefits to use Kesimpta® and for which patients
Early switch from teriflunomide to Kesimpta®
no subtitles
Discover the benefits to use Kesimpta® early on
Early switch from teriflunomide to Kesimpta®
EN subtitles
Discover the benefits to use Kesimpta® early on - FR spoken with English subtitles
Treatment switch from Gilenya® to Kesimpta®
no subtitles
Discover the benefits of anti-CD20 subcutaneous administration after Gilenya® cessation – FR spoken
Treatment switch from Gilenya® to Kesimpta®
EN subtitles
Discover the benefits of anti-CD20 subcutaneous administration after Gilenya® cessation - FR spoken with English subtitles
First line switch from dimethyl fumarate to Kesimpta®
Discover the benefits to use Kesimpta® early on - FR spoken
First line switch from dimethyl fumarate to Kesimpta®
EN subtitles
Discover the benefits to use Kesimpta® early on - FR spoken with English subtitles
Increased tolerability: ocrelizumab to Kesimpta®
The increased tolerability from Kesimpta® over ocrelizumab thanks to absence of pre-medication – FR spoken
Increased tolerability: ocrelizumab to Kesimpta®
EN subtitles
The increased tolerability from Kesimpta® over ocrelizumab thanks to absence of pre-medication - FR spoken with English subtitles
Treatment switch from cladribine, to Kesimpta®
Switch from Cladribine to Kesimpta ® due to a disease re-activation - Dutch spoken
Treatment switch from cladribine, to Kesimpta®
EN subtitles
Switch from Cladribine to Kesimpta ® due to a disease re-activation - Dutch spoken with English subtitles
Treatment switch from Gilenya® to Kesimpta®
no subtitles
Reduce the rebound risk after Gilenya® cessation with a switch to Kesimpta® - Dutch spoken
Treatment switch from Gilenya® to Kesimpta®
EN subtitles
Reduce the rebound risk after Gilenya® cessation with a switch to Kesimpta® - Dutch spoken with English subtitles
BrainBreak: Invisible symptoms of MS by Prof. Dr. Bart Van Wijmeersch (15.58 minutes) - EN
BrainBreak: EAN Congress Highlights by Dr. Serena Borrelli (25.20 minutes) - FR
BrainBreak: MS en Seksuologie with Dr An-Sofie de Boi (18.46 minutes) - NL
BrainBreak: MS en Urologie with Dr Elizabeth Pauwels (26.36 minutes) - NL
BrainBreak: Hot Topics ECTRIMS 2023 by Prof. Dominique Dive (31.38 minutes) - FR
Novartis symposium at ECTRIMS 2022
Watch the Novartis symposium at ECTRIMS 2022 and download some posters on Kesimpta – Mayzent that were presented during the congress in Amsterdam.
Novartis Satellite Symposium : Ofatumumab in clinical practice: Expert experience & case-based discussion
(7x 3 minutes)
Does high efficacy equate with high risk? (3.09 minutes)
Ofatumumab and immune maintenance (1.44 minutes)
Advantages of Ofatumumab from the patient perspective (2.39 minutes)
Case study: Switching for efficacy (3.11 minutes)
Case study: Choosing therapy for a treatment- naive patient & taking into account their preference (3.07 minutes)
Case study: Switching a patient taking into account their preferences (2.54 minutes)
Treatment choice & management: Are the ‘red flags’ for active disease changing? (2.05 minutes)
Posters
Download here the Ofatumumab posters
Compliance and Persistence data for up to 4 year
Efficacy of Early VS late switches analysis by prior DMT exposure
Download here the Amasia study – Real world insights on Siponimod
Novartis Break-out session during NeuroVision
Watch the Novartis Break-out session during NeuroVision – Listen to the practical cases from Dr. David Paling (UK) and his key take-aways of Kesimpta®
Novartis Break-out session: High efficacy treatments early in MS: Real Life experience with Kesimpta® (30.23 minutes)
Kesimpta®: hands-on insights
Find here the recording of our sponsored break-out session during the 7th ParadigMS – congress.
Dr. M. Cambron shares with us her insight on the use of Kesimpta and some practical cases.
Ofatumumab: Hands-on insights with Dr. Cambron (28.16 minutes)
MS Vision 2022
Join us and prof. P. Vermersch during a webinar hosted on the 9th of June where he shared is vision on HET in MS for 2022. He presented usefull cases in France and reflected on the different HET that are on the market today.
Kesimpta, un traitement de haute efficacité dans la SEP – Prof. Vermersch (69 minutes)
EAN Symposium: HET, why wait?
We’re happy to share with you the three sessions that were hosted by Novartis during EAN ’22 in Vienna.
High efficacy Early: what are we waiting for? (13.47 minutes
High efficacy Early: Time to re-evalutate the compromise between efficacy and safety? (13.25 minutes
The patient perspective on MS treatment: What matters most? (18.09 minutes
ASCLEPIOS data for Kesimpta
Find here the series of 7 short videos with Professor Stephen Hauser covering a range of topics including disease state education and the ASCLEPIOS data for Kesimpta.
The current state of MS Therapeutics (3.36 minutes)
The role of B cells in the MS Pathology (6.29 minutes)
Implications of the ASCLEPIOS Trial (19.12 minutes)
B Cell Therapies and the MS Armamentarium (7.33 minutes)
The takeway from the ACSLEPIOS Study (6.09 minutes)
Anti-CD20 therapies (3.49 minutes)
MS Pathology and our Understanding of Progression (5.54 minutes)
Benefits of treating MS patients early with HET
Prof. Dive (French spoken)
Benefits of High Efficacy treatments – early on (5.27 minutes)
Poor prognostic factors in MS and their implications (5.21 minutes)
Kesimpta® a new high efficacy treatment for early use in MS (5.46 minutes)
MS & cognition
Learn more about MS & cognition
Watch the series of short videos from Prof. Iris Katherina Penner, cognitive neuroscientist, neuropsychologist.
When in the MS journey can cognitive changes occur? (1.07 minutes)
How likely are people with MS to experience cognitive changes? (2.30 minutes)
What do cognitive changes look like in MS and how do they manifest? (2.40 minutes)
Do caregivers play a role in identifying cognitive symptoms in people with MS? (46 minutes)
Are there any challenges in identifying cognitive changes in people with MS? (45 minutes)
We recommend you to watch the webinar ‘Assessment of treatment response’ from The European Charcot Foundation sponsored by Novartis.
This webinar is accredited by the European Accreditation Council for Continuing Medical Education (EACCME).
ECF Webinar 2022: Assessment of Treatment Response (1h16 minutes)
ECF Webinar 2022: Assessment of Treatment Response | European Charcot Foundation
(charcot-ms.org)
By clicking on the link you will be redirect to the website of ECF. A registration on the website is required to be able to watch the webinar.